These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 165029)

  • 1. Dose-response to tibric acid: a new hypolipidemic drug in type IV hyperlipoproteinemia.
    Bielmann P; Brun D; Moorjani S; Gagné C; Lupien P; Tétreault L
    Clin Pharmacol Ther; 1975 May; 17(5):606-11. PubMed ID: 165029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia.
    Bielmann P; Brun D; Moorjani S; Gagnon MA; Tétreault L; Lupien PJ
    Int J Clin Pharmacol Biopharm; 1977 Apr; 15(4):166-71. PubMed ID: 192685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of tibric acid (CP 18,524) a new hypolipidemic agent.
    Sirtori CR; Zoppi S; Quarisa B; Agradi E
    Pharmacol Res Commun; 1974 Oct; 6(5):445-56. PubMed ID: 4617230
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of hypertriglyceridemia with tibric acid and clofibrate. Cross-over studies, effects on lipoproteins and absence of post-drug rebound.
    Smith FR; Noble RP; Goodman DS
    Atherosclerosis; 1978 Mar; 29(3):345-54. PubMed ID: 666884
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of tibric acid (CP-18.254) on plasma lipids in patients with primary endogenous hyperlipoproteinemia].
    Lisch HJ; Sailer S; Braunsteiner H
    Arzneimittelforschung; 1977; 27(10):2017-20. PubMed ID: 579116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of hyperlipemia with tibric acid (TA)].
    De Rosa L; Giangrandi E; Murante N; Scaroina F
    Minerva Med; 1978 Jun; 69(28):1917-22. PubMed ID: 208024
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical trial of tibric acid, a new hypolipidemic agent].
    Noseda G; Sirtori CR
    Schweiz Med Wochenschr; 1974 Dec; 104(51):1917-22. PubMed ID: 4438990
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study.
    Vahlquist C; Olsson AG; Lindholm A; Vahlquist A
    Acta Derm Venereol; 1995 Sep; 75(5):377-80. PubMed ID: 8615057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinaemia.
    Maebashi M; Kawamura N; Sato M; Imamura A; Yoshinaga K
    Lancet; 1978 Oct; 2(8094):805-7. PubMed ID: 81361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypolipemic effect of diosponine in ischemic heart disease depending on the type of hyperlipoproteinemia].
    Zakharov VN
    Kardiologiia; 1977 Jun; 17(6):136-7. PubMed ID: 197285
    [No Abstract]   [Full Text] [Related]  

  • 11. A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).
    Neuman J; de Neuman MP; Talmasky S; Pesce R; Valero E; Martiarena JL
    J Cardiovasc Surg (Torino); 1973; Spec No():532-7. PubMed ID: 4377715
    [No Abstract]   [Full Text] [Related]  

  • 12. Colestipol in familial type II hyperlipoproteinemia: a three-year trial.
    Harvengt C; Desager JP
    Clin Pharmacol Ther; 1976 Sep; 20(3):310-4. PubMed ID: 182429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term use of gemfibrozil (Lopid) in the treatment of dyslipidemia.
    Lewis JE
    Angiology; 1982 Sep; 33(9):603-12. PubMed ID: 6957156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of vitamin E on serum cholesterol and triglycerides in hyperlipidemic patients treated with diet and clofibrate.
    Leonhardt ET
    Am J Clin Nutr; 1978 Jan; 31(1):100-5. PubMed ID: 202160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA; Azarnoff DL; Huffman DH; Pentikäinen P; Hurwitz A; Shoeman DW
    Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of primary hyperlipoproteinemia types IIa, IIb and IV using beta pyridylcarbinol Study on three phases under ambulatory conditions].
    Klemens UH; von Löwis P
    Dtsch Med Wochenschr; 1973 Jun; 98(24):1197-202. PubMed ID: 4350685
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of gemfibrozil on serum lipids in man.
    Fenderson RW; Deutsch S; Menachemi E; Chin B; Samuel P
    Angiology; 1982 Sep; 33(9):581-93. PubMed ID: 6751166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of halofenate on serum lipids.
    Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP; Mays J
    Clin Pharmacol Ther; 1973; 14(3):358-65. PubMed ID: 4572798
    [No Abstract]   [Full Text] [Related]  

  • 19. Lowering of serum cholesterol and triglyceride by para-aminosalicylic acid in hyperlipoproteinemia. Studies in patients with types II-A and II-B.
    Barter PJ; Connor WE; Spector AA; Armstrong M; Connor SL; Newman MA
    Ann Intern Med; 1974 Nov; 81(5):619-24. PubMed ID: 4609028
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of primary hyperlipoproteinemias type IV with different biguanides (author's transl)].
    Weisweiler P; Schwandt P
    Klin Wochenschr; 1976 Mar; 54(6):283-5. PubMed ID: 177803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.